VISEN Pharmaceuticals (Incorporated in the Cayman Islands with limited liability) filed its monthly return with Hong Kong Exchanges and Clearing Limited for the period ended 30 September 2026, confirming no movements in its share capital during the month.

The company’s authorised share capital remained at 500.00 million ordinary shares with a par value of USD 0.0001, translating into total authorised capital of USD 50,000. Issued share capital was unchanged at 113.75 million shares (excluding 0.17 million treasury shares), keeping the total number of issued shares at 113.93 million.

VISEN affirmed compliance with the Main Board’s minimum public-float requirement of 25%. No share options, warrants, convertibles, or other equity instruments were exercised or issued in the period. Under the Post-IPO Share Award Scheme adopted on 16 November 2022, the maximum number of shares that may be issued upon vesting of all outstanding awards stands at 2.40 million; however, no shares were issued or transferred in September.

The filing, signed by Executive Director Lu An-Bang on 6 October 2026, also reconfirmed that all requisite regulatory and listing rule obligations have been met.